226 related articles for article (PubMed ID: 35294217)
1. Fetal anatomy scan with integrated nuchal translucency and combination of PAPP-A and fβhCG for prediction of aneuploidy.
Kornanova E; Dugatova M; Vaclavova Z; Borovsky M
Bratisl Lek Listy; 2022; 123(4):299-303. PubMed ID: 35294217
[TBL] [Abstract][Full Text] [Related]
2. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
3. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
Audibert F; Gagnon A; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
[TBL] [Abstract][Full Text] [Related]
4. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
[TBL] [Abstract][Full Text] [Related]
5. [Prospective cohort study of fetal nuchal translucency in first-trimester and pregnancy outcome].
Tang HR; Zhang Y; Ru T; Li J; Yang L; Xu Y; Duan HL; Wang Y; Wang Y; Hu YL; Zhang Y; Zheng MM
Zhonghua Fu Chan Ke Za Zhi; 2020 Feb; 55(2):94-99. PubMed ID: 32146737
[No Abstract] [Full Text] [Related]
6. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
[TBL] [Abstract][Full Text] [Related]
7. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
8. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
[TBL] [Abstract][Full Text] [Related]
9. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
[TBL] [Abstract][Full Text] [Related]
10. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
11. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
12. [Noninvasive prenatal test in the first trimester of pregnancy (NT and estimation of beta-hCG and PAPP-A) in the diagnosis of fetal abnormalities in Polish population--comparison of the biochemistry own normal ranges and literature reported data].
Mandryka-Stankewycz S; Perenc M; Dec G; Sieroszewski P
Ginekol Pol; 2009 Nov; 80(11):851-5. PubMed ID: 20088400
[TBL] [Abstract][Full Text] [Related]
13. Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies.
Giorgetti C; Vanden Meerschaut F; De Roo C; Saunier O; Quarello E; Hairion D; Penaranda G; Chabert-Orsini V; De Sutter P
Hum Reprod; 2013 Oct; 28(10):2636-42. PubMed ID: 23887070
[TBL] [Abstract][Full Text] [Related]
14. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
15. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
16. Should cell-free DNA testing be used in pregnancy with increased fetal nuchal translucency?
Miranda J; Paz Y Miño F; Borobio V; Badenas C; Rodriguez-Revenga L; Pauta M; Borrell A
Ultrasound Obstet Gynecol; 2020 May; 55(5):645-651. PubMed ID: 31301176
[TBL] [Abstract][Full Text] [Related]
17. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K; Cicero S; Atzei A; Otigbah C; Nicolaides KH
Prenat Diagn; 2005 Oct; 25(10):927-9. PubMed ID: 16088864
[TBL] [Abstract][Full Text] [Related]
18. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities.
Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG
Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700
[TBL] [Abstract][Full Text] [Related]
19. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
20. The added value of detailed early anomaly scan in fetuses with increased nuchal translucency.
Zalel Y; Zemet R; Kivilevitch Z
Prenat Diagn; 2017 Mar; 37(3):235-243. PubMed ID: 28010037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
